Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

430P - Aurora kinase A (AURKA) expression in patients with nasopharyngeal cancers: Its association with clinical characteristics and treatment responses

Date

07 Dec 2024

Session

Poster Display session

Presenters

Kartika Taroeno-Hariadi

Citation

Annals of Oncology (2024) 35 (suppl_4): S1554-S1574. 10.1016/annonc/annonc1692

Authors

K.W. Taroeno-Hariadi

Author affiliations

  • Department Of Internal Medicine, Division Of Hematology And Medical Oncology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada / Dr. Sardjito General Hospital, 55281 - Yogyakarta/ID

Resources

This content is available to ESMO members and event participants.

Abstract 430P

Background

Aurora kinase A (AURKA) is a serine/threonine kinase involved in many biological processes such as in G2/M transition, mitotic spindle assembly and DNA replication. AURKA is expressed in many cancer types and associated with worse treatment outcome. This study aims to explore the expressions of AURKA in nasopharyngeal cancer (NPC) tissues, and to find the association with patients' clinical characters and treatment responses.

Methods

The formalin-fixed paraffine embedded tissues from adult NPC patients were selected for immunohistochemistry test. A polyclonal, rabbit AURKA antibody (FNab10043) was used for detecting AURKA expression. The visible cellular brown staining was considered as a positive expression. A semi-quantitative evaluation of immunohistochemical staining was calculated based on the intensity and extent of staining. The merged overall scores ≥ 5 were classified as high staining, while scores ≤ 4 were regarded as low staining. The immunohistochemical staining scores were evaluated by 2 independent pathologists. Clinical characters such as tumor stage, nodal stage, and response to standard treatment were analyzed based on AURKA immunohistochemical staining scores.

Results

There were 64 NPC patients with available FFPE tissues. Thirty-six (56.3%) tissue samples expressed high staining AURKA. High-staining expression of AURKAs had tendencies to be found in advanced stages compared to early stages (56.8% vs.43.2%; p = 0.924). Samples from NPC patients with distant metastasis at first presentation had more high-staining expressions (67.7% vs. 33.3%; p = 0.497). The clinical benefit rate of standard treatment for NPC was lower in the high-staining group compared to the low-staining group (72.7% vs. 92.8%; p <0.024).

Conclusions

AURKAs were expressed abundantly in NPC tissues. High immunostaining score of AURKA was significantly associated with lower clinical benefit rate of a standard NPC treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.